Individualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study

Ida Marie Lind Rasmussen, Anne Vest Soerensen, Anne Kirstine Møller, Gitte Fredberg Persson, Jesper Andreas Palshof, Gry Assam Taarnhøj, Helle Pappot, Ida Marie Lind Rasmussen, Anne Vest Soerensen, Anne Kirstine Møller, Gitte Fredberg Persson, Jesper Andreas Palshof, Gry Assam Taarnhøj, Helle Pappot

Abstract

Background: No phase 3 studies have yet been conducted for patients with non-clear cell (CC) renal cell carcinoma (RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumor morphology. Consequently, there is no evidence of the optimal treatment, and new approaches are needed. One approach is individualizing treatment based on the gene sequencing of tumor tissue. Additionally, recent studies involving the patient-reported outcomes (PROs) of patients treated for metastatic cancer have shown significant benefits for quality of life, median overall survival, and overall survival. The use of gene sequencing and PROs can be of great importance to patients with rare cancer types, including patients with non-CC RCC, and should be investigated in clinical trials, especially for cases where evidence based on phase 3 studies is difficult to obtain.

Objective: We describe the INDIGO study, in which patients, based on gene analyses, will be allocated into 4 treatment arms containing 14 treatments and use electronic PROs. We aim to improve the treatment of patients with non-CC RCC. The end points in the study will be the overall response rate (complete and partial) in the total patient population, which will be based on the RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria, and the time to treatment failure.

Methods: INDIGO is a prospective phase 2 trial, and 30 patients will be enrolled. The patients will receive systemic treatment based on genetic analyses of their tumor tissue. All patients will receive electronic questionnaires in a dedicated app-a questionnaire regarding symptoms and side effects and another regarding health-related quality of life. Depending on the treatment regimen, the patients will be seen by a medical doctor every third, fourth, or sixth week, and the effect of the systemic treatment will be evaluated every 6 weeks via a computed tomography scan. The study has been approved by the Danish Medicines Agency and the National Committee on Health Research Ethics (approval number: H-19041833), complies with good clinical practice guidelines, follows the General Data Protection Regulation, and is registered at the Capital Region of Denmark.

Results: Recruitment started in March 2020, and at the time of submitting this paper (June 2022), a total of 9 patients have been enrolled.

Conclusions: We aim to explore methods for improving the treatment outcomes of patients with non-CC RCC, and the INDIGO study will contribute further data on personalized medicine for rare types of RCC and provide new knowledge on the active use of electronic PROs.

Trial registration: ClinicalTrials.gov NCT04644432, https://ichgcp.net/clinical-trials-registry/NCT04644432 ; European Union Drug Regulating Authorities Clinical Trials Database 2019-001316-38, https://tinyurl.com/2p8mb4aw.

International registered report identifier (irrid): DERR1-10.2196/36632.

Keywords: eHealth; electronic patient-reported outcome; health-related quality of life; non–clear cell renal cell carcinoma; oncology; outcome; patient-reported; patient-reported outcome; precision medicine; renal cell carcinoma; targeted therapy.

Conflict of interest statement

Conflicts of Interest: The INDIGO study is financially supported by Roche Pharmaceuticals and The Capital Region of Denmark. None of the authors are funded by Roche Pharmaceuticals.

©Ida Marie Lind Rasmussen, Anne Vest Soerensen, Anne Kirstine Møller, Gitte Fredberg Persson, Jesper Andreas Palshof, Gry Assam Taarnhøj, Helle Pappot. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 15.09.2022.

Figures

Figure 1
Figure 1
INDIGO study design and flow. CT: computed tomography; IC: informed consent; NGS: next-generation sequencing; RNA: Ribonucleic Acid.
Figure 2
Figure 2
Patient interface in the Journl app. Text has been translated to English.
Figure 3
Figure 3
Clinician interface in the Journl web application. Text has been translated to English.

References

    1. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A, ESMO Guidelines Committee Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 May 01;30(5):706–720. doi: 10.1093/annonc/mdz056. S0923-7534(19)31157-3
    1. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DYC. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013 Aug 15;119(16):2999–3006. doi: 10.1002/cncr.28151. doi: 10.1002/cncr.28151.
    1. Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK. Non-clear cell renal cell carcinomas: From shadow to light. J Clin Oncol. 2018 Oct 29;:JCO2018792531. doi: 10.1200/JCO.2018.79.2531.
    1. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar;17(3):378–388. doi: 10.1016/S1470-2045(15)00515-X. S1470-2045(15)00515-X
    1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 09;372(9637):449–456. doi: 10.1016/S0140-6736(08)61039-9.S0140-6736(08)61039-9
    1. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008 Jan 01;26(1):127–131. doi: 10.1200/JCO.2007.13.3223.26/1/127
    1. McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021 Mar 20;39(9):1029–1039. doi: 10.1200/JCO.20.02365.
    1. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116–1127. doi: 10.1056/NEJMoa1816714.
    1. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Gordoa TA, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK, CLEAR Trial Investigators Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021 Apr 08;384(14):1289–1300. doi: 10.1056/NEJMoa2035716.
    1. Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 05;378(14):1277–1290. doi: 10.1056/NEJMoa1712126.
    1. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Juárez VMO, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, CheckMate 9ER Investigators Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021 Mar 04;384(9):829–841. doi: 10.1056/NEJMoa2026982.
    1. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007 Nov 10;25(32):5121–5127. doi: 10.1200/JCO.2007.12.4784.25/32/5121
    1. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov;7(11):903–909. doi: 10.1016/S1470-2045(06)70910-X.S1470-2045(06)70910-X
    1. Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015 Mar 10;33(8):910–915. doi: 10.1200/JCO.2014.57.9334.JCO.2014.57.9334
    1. Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010 Jun 21;340:c2921. doi: 10.1136/bmj.c2921.
    1. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016 Feb 20;34(6):557–565. doi: 10.1200/JCO.2015.63.0830. JCO.2015.63.0830
    1. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017 Jul 11;318(2):197–198. doi: 10.1001/jama.2017.7156. 2630810
    1. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) J Natl Cancer Inst. 2014 Sep 29;106(9):dju244. doi: 10.1093/jnci/dju244. dju244
    1. Bæksted C, Nissen A, Pappot H, Bidstrup PE, Mitchell SA, Basch E, Dalton SO, Johansen C. Danish translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) J Pain Symptom Manage. 2016 Aug;52(2):292–297. doi: 10.1016/j.jpainsymman.2016.02.008. S0885-3924(16)30045-8
    1. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749–757. doi: 10.1038/s41591-018-0053-3. 10.1038/s41591-018-0053-3
    1. Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, Mariathasan S, Green M, Tayama D, Hegde PS, Schiff C, Huseni MA, Rini B. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020 Dec 14;38(6):803–817.e4. doi: 10.1016/j.ccell.2020.10.011. S1535-6108(20)30542-0
    1. Tolstrup LK, Pappot H, Zangger G, Bastholt L, Zwisler AD, Dieperink KB. Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form. Health Qual Life Outcomes. 2018 Apr 27;16(1):77. doi: 10.1186/s12955-018-0900-4. 10.1186/s12955-018-0900-4
    1. Soerensen AV, Donskov F, Hermann GG, Jensen NV, Petersen A, Spliid H, Sandin R, Fode K, Geertsen PF. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer. 2014 Feb;50(3):553–562. doi: 10.1016/j.ejca.2013.10.010. S0959-8049(13)00948-9
    1. Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P, Carter R, Gibson A, Holmes M, Clayton B, Rogers Z, McParland L, Conner M, Glidewell L, Woroncow B, Dawkins B, Dickinson S, Hulme C, Brown J, Velikova G. Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol. 2021 Mar 01;39(7):734–747. doi: 10.1200/JCO.20.02015.
    1. Maguire R, McCann L, Kotronoulas G, Kearney N, Ream E, Armes J, Patiraki E, Furlong E, Fox P, Gaiger A, McCrone P, Berg G, Miaskowski C, Cardone A, Orr D, Flowerday A, Katsaragakis S, Darley A, Lubowitzki S, Harris J, Skene S, Miller M, Moore M, Lewis L, DeSouza N, Donnan PT. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART) BMJ. 2021 Jul 21;374:n1647. doi: 10.1136/bmj.n1647.
    1. Denis F, Basch E, Septans AL, Bennouna J, Urban T, Dueck AC, Letellier C. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019 Jan 22;321(3):306–307. doi: 10.1001/jama.2018.18085. 2721170
    1. Nissen A, Bager L, Pappot H. The use of PRO in adverse event identification during cancer therapy - choosing the right questions to ask. Acta Oncol. 2019 May;58(5):596–602. doi: 10.1080/0284186X.2018.1560496.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj